Print

Cyclacel Pharmaceuticals, Inc. (CYCC) to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting  
5/17/2012 9:52:57 AM

BERKELEY HEIGHTS, N.J., May 17, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today that new clinical data for oral sapacitabine capsules, the Company's lead product candidate, will be presented as posters during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012, in Chicago, Illinois.